{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:48:13Z","timestamp":1770814093016,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Collaborative Innovation Project","award":["XTCX-KJ-2023-44"],"award-info":[{"award-number":["XTCX-KJ-2023-44"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04366-2","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:00:55Z","timestamp":1767632455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of PCMT1 in prognosis tumor immune microenvironment and therapeutic responses across cancers"],"prefix":"10.1007","volume":"17","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruizhen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwen","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"3","key":"4366_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4366_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4366_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CEJ.0000000000000594","volume":"29","author":"C Santucci","year":"2020","unstructured":"Santucci C, Carioli G, Bertuccio P, Malvezzi M, Pastorino U, Boffetta P, et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29(5):367\u201381.","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"4366_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16\u201327.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"4366_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"4366_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117141","volume":"283","author":"B Cheng","year":"2025","unstructured":"Cheng B, Lv J, Xiao Y, Song C, Chen J, Shao C. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024). Eur J Med Chem. 2025;283:117141.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"4366_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2444697","volume":"21","author":"FJ Huang","year":"2025","unstructured":"Huang FJ, Fang YY, Wen JY, Li JJ, Lin Q, Su QY, et al. From PD-1\/PD-L1 to tertiary lymphoid structures: paving the way for precision immunotherapy in cholangiocarcinoma treatment. Hum Vaccin Immunother. 2025;21(1):2444697.","journal-title":"Hum Vaccin Immunother"},{"key":"4366_CR8","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476.","journal-title":"Front Immunol"},{"key":"4366_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"4366_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1874609811104010008","volume":"4","author":"RR Desrosiers","year":"2011","unstructured":"Desrosiers RR, Fan\u00e9lus I. Damaged proteins bearing L-isoaspartyl residues and aging: a dynamic equilibrium between generation of isomerized forms and repair by PIMT. Curr Aging Sci. 2011;4(1):8\u201318.","journal-title":"Curr AgingSci"},{"key":"4366_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001156","author":"I Gonz\u00e1lez-Recio","year":"2024","unstructured":"Gonz\u00e1lez-Recio I, Goikoetxea-Usandizaga N, Rejano-Gordillo CM, Conter C, Rodr\u00edguez Agudo R, Serrano-Maci\u00e1 M, et al. Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damage. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000001156.","journal-title":"Hepatology"},{"issue":"12","key":"4366_CR12","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1248\/yakushi.127.1927","volume":"127","author":"T Furuchi","year":"2007","unstructured":"Furuchi T, Homma H. Role of isomerized protein repair enzyme, PIMT, in cellular functions. Yakugaku Zasshi. 2007;127(12):1927\u201336.","journal-title":"Yakugaku Zasshi"},{"key":"4366_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228545","author":"V Simko","year":"2020","unstructured":"Simko V, Belvoncikova P, Csaderova L, Labudova M, Grossmannova K, Zatovicova M, et al. PIMT binding to C-terminal Ala459 of CAIX is involved in inside-out signaling necessary for its catalytic activity. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21228545.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4366_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s100380050161","volume":"44","author":"CG DeVry","year":"1999","unstructured":"DeVry CG, Clarke S. Polymorphic forms of the protein L-isoaspartate (D-aspartate) O-methyltransferase involved in the repair of age-damaged proteins. J Hum Genet. 1999;44(5):275\u201388.","journal-title":"J Hum Genet"},{"key":"4366_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051485","author":"Y Jia","year":"2018","unstructured":"Jia Y, Liu N, Viswakarma N, Sun R, Schipma MJ, Shang M, et al. PIMT\/NCOA6IP deletion in the mouse heart causes delayed cardiomyopathy attributable to perturbation in energy metabolism. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19051485.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4366_CR16","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1021\/pr400688r","volume":"12","author":"H Yang","year":"2013","unstructured":"Yang H, Lowenson JD, Clarke S, Zubarev RA. Brain proteomics supports the role of glutamate metabolism and suggests other metabolic alterations in protein l-isoaspartyl methyltransferase (PIMT)-knockout mice. J Proteome Res. 2013;12(10):4566\u201376.","journal-title":"J Proteome Res"},{"issue":"4","key":"4366_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/iub.1717","volume":"70","author":"L Dong","year":"2018","unstructured":"Dong L, Li Y, Xue D, Liu Y. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer. IUBMB Life. 2018;70(4):291\u20139.","journal-title":"IUBMB Life"},{"key":"4366_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2015.11.006","volume":"50","author":"H Saito","year":"2016","unstructured":"Saito H, Yamashita M, Ogasawara M, Yamada N, Niisato M, Tomoyasu M, et al. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma. Hum Pathol. 2016;50:1\u201310.","journal-title":"Hum Pathol"},{"issue":"1","key":"4366_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-022-02242-3","volume":"41","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li Y, Liu H, Zhang J, Wang J, Xia J, et al. Genome-wide CRISPR\/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis. J Exp Clin Cancer Res. 2022;41(1):24.","journal-title":"J Exp Clin Cancer Res"},{"key":"4366_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4434887","volume":"2022","author":"J Guo","year":"2022","unstructured":"Guo J, Du X, Li C. PCMT1 is a potential prognostic biomarker and is correlated with immune infiltrates in breast cancer. Biomed Res Int. 2022;2022:4434887.","journal-title":"Biomed Res Int"},{"issue":"6","key":"4366_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14559","volume":"103","author":"K Zhang","year":"2024","unstructured":"Zhang K, Li JY, Li K. Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K\/Akt\/STMN1 pathway. Chem Biol Drug Des. 2024;103(6):e14559.","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"4366_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/0109298665315841240731060636","volume":"31","author":"X Deng","year":"2024","unstructured":"Deng X, Ma N, He J, Xu F, Zou G. The role of TGFBR3 in the development of lung cancer. Protein Pept Lett. 2024;31(7):491\u2013503.","journal-title":"Protein Pept Lett"},{"issue":"9","key":"4366_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye W, Wang J, Zheng J, Jiang M, Zhou Y, Wu Z. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Peptide Lett. 2024;31(9):706\u201313.","journal-title":"Protein Peptide Lett"},{"key":"4366_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mdr2.70004","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang G, Xu P, Yu F, Li L, Huang R, et al. Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes. Med Res. 2025. https:\/\/doi.org\/10.1002\/mdr2.70004.","journal-title":"Med Res"},{"issue":"5","key":"4366_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2174\/0113892029300694240612081006","volume":"25","author":"Q Li","year":"2024","unstructured":"Li Q, Chu Y, Yao Y, Song Q. FAT4 mutation is related to tumor mutation burden and favorable prognosis in gastric cancer. Curr Genomics. 2024;25(5):380\u20139.","journal-title":"Curr Genomics"},{"key":"4366_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mdr2.70040","author":"X Ke","year":"2025","unstructured":"Ke X, Li K, Jiang A, Zhang Y, Wang Q, Li Z, et al. Cloud-based GWAS platform: an innovative solution for efficient acquisition and analysis of genomic data. Med Res. 2025. https:\/\/doi.org\/10.1002\/mdr2.70040.","journal-title":"Med Res"},{"issue":"1","key":"4366_CR27","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","volume":"9","author":"MA Lakins","year":"2018","unstructured":"Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T cells to protect tumour cells. Nat Commun. 2018;9(1):948.","journal-title":"Nat Commun"},{"issue":"1","key":"4366_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"key":"4366_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811559","volume":"12","author":"X Ding","year":"2022","unstructured":"Ding X, Liu H, Yuan Y, Zhong Q, Zhong X. Roles of GFPT2 expression levels on the prognosis and tumor microenvironment of colon cancer. Front Oncol. 2022;12:811559.","journal-title":"Front Oncol"},{"key":"4366_CR30","first-page":"1","volume":"2017","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Prec Oncol. 2017;2017:1.","journal-title":"JCO Prec Oncol"},{"issue":"2","key":"4366_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-54 e15.","journal-title":"Cell."},{"issue":"Database issue","key":"4366_CR32","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955-61.","journal-title":"Nucleic Acids Res"},{"key":"4366_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac558","author":"CJ Liu","year":"2023","unstructured":"Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y, et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2023. https:\/\/doi.org\/10.1093\/bib\/bbac558.","journal-title":"Brief Bioinform"},{"key":"4366_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina56010015","volume":"56","author":"B Arneth","year":"2019","unstructured":"Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56:15\u201324.","journal-title":"Medicina (Kaunas)."},{"issue":"8","key":"4366_CR35","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.21037\/tcr-21-2700","volume":"11","author":"L Shan","year":"2022","unstructured":"Shan L, Wang X, Li Y, Li L, Wu S, Xi X, et al. Elevated expression of protein-L-isoaspartate O-methyltransferase-1 (PCMT1) in cervical cancer. Transl Cancer Res. 2022;11(8):2582\u201390.","journal-title":"Transl Cancer Res"},{"key":"4366_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105698","author":"F Belkourchia","year":"2022","unstructured":"Belkourchia F, Desrosiers RR. The protein L-isoaspartyl (D-aspartyl) methyltransferase regulates glial-to-mesenchymal transition and migration induced by TGF-\u03b21 in human U-87 MG glioma cells. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23105698.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4366_CR37","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1681\/ASN.0000000652","volume":"36","author":"J Xia","year":"2025","unstructured":"Xia J, Hou Y, Wang J, Zhang J, Wu J, Yu X, et al. Repair of isoaspartyl residues by PCMT1 and kidney fibrosis. J Am Soc Nephrol. 2025;36(7):1278\u201394.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4366_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","volume":"24","author":"MS Hipp","year":"2014","unstructured":"Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 2014;24(9):506\u201314.","journal-title":"Trends Cell Biol"},{"issue":"3-4","key":"4366_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/prca.201200086","volume":"7","author":"SM Thompson","year":"2013","unstructured":"Thompson SM, Craven RA, Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteom Clin Appl. 2013;7(3\u20134):241\u201351.","journal-title":"Proteom Clin Appl"},{"issue":"3","key":"4366_CR40","first-page":"167","volume":"25","author":"A Suvac","year":"2025","unstructured":"Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25(3):167\u201388.","journal-title":"Nat Rev Cancer"},{"key":"4366_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217484","volume":"612","author":"S Chaudhary","year":"2025","unstructured":"Chaudhary S, Siddiqui JA, Pothuraju R, Bhatia R. Ribosome biogenesis, altered metabolism and ribotoxic stress response in pancreatic ductal adenocarcinoma tumor microenvironment. Cancer Lett. 2025;612:217484.","journal-title":"Cancer Lett"},{"issue":"6","key":"4366_CR42","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4366_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ijc.30425","volume":"140","author":"NC Synnott","year":"2017","unstructured":"Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O\u2019Donovan N, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234\u201346.","journal-title":"Int J Cancer"},{"issue":"7","key":"4366_CR44","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41416-023-02321-y","volume":"129","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. Br J Cancer. 2023;129(7):1041\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"4366_CR45","doi-asserted-by":"publisher","first-page":"2452654","DOI":"10.1080\/2162402X.2025.2452654","volume":"14","author":"K Tanigawa","year":"2025","unstructured":"Tanigawa K, Redmond WL. Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy. Oncoimmunology. 2025;14(1):2452654.","journal-title":"Oncoimmunology"},{"key":"4366_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156834","volume":"186","author":"RG Khalil","year":"2025","unstructured":"Khalil RG, Mohammed DA, Hamdalla HM, Ahmed OM. The possible anti-tumor effects of regulatory T cells plasticity \/ IL-35 in the tumor microenvironment of the major three cancer types. Cytokine. 2025;186:156834.","journal-title":"Cytokine"},{"issue":"8","key":"4366_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437\u201354.","journal-title":"Nat Rev Cancer"},{"key":"4366_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012069","author":"P Zhang","year":"2025","unstructured":"Zhang P, Zhang M, Liu J, Zhou Z, Zhang L, Luo P, et al. Mitochondrial pathway signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012069.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4366_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/0113892029291247240422060811","volume":"25","author":"M Jiang","year":"2024","unstructured":"Jiang M, Zhu D, Zhao D, Liu Y, Li J, Zheng Z. Integrated analysis of clinical outcome of mesenchymal stem cell-related genes in pan-cancer. Curr Genomics. 2024;25(4):298\u2013315.","journal-title":"Curr Genomics"},{"issue":"1","key":"4366_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/bjc.2016.161","volume":"115","author":"CG Kim","year":"2016","unstructured":"Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115(1):25\u201333.","journal-title":"Br J Cancer"},{"issue":"3","key":"4366_CR51","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1245\/s10434-015-4931-3","volume":"23","author":"D Marrelli","year":"2016","unstructured":"Marrelli D, Polom K, Pascale V, Vindigni C, Piagnerelli R, De Franco L, et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann Surg Oncol. 2016;23(3):943\u201350.","journal-title":"Ann Surg Oncol"},{"key":"4366_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","author":"SK Yoo","year":"2025","unstructured":"Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03398-5.","journal-title":"Nat Med"},{"key":"4366_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155743","volume":"265","author":"S Vickram","year":"2025","unstructured":"Vickram S, Infant SS, Manikandan S, Jenila Rani D, Mathan Muthu CM, Chopra H. Immune biomarkers and predictive signatures in gastric cancer: optimizing immunotherapy responses. Pathol Res Pract. 2025;265:155743.","journal-title":"Pathol Res Pract"},{"key":"4366_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082273","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu P, Xu L, Zhang X, Li Z, Li Y, et al. Current progress on predictive biomarkers for response to immune checkpoint inhibitors in gastric cancer: how to maximize the immunotherapeutic benefit? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15082273.","journal-title":"Cancers (Basel)"},{"key":"4366_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466806","volume":"15","author":"D Huang","year":"2024","unstructured":"Huang D, Li J, He Z, Liang W, Zhong L, Huang J, et al. Pan-cancer and experimental analyses reveal the immunotherapeutic significance of CST2 and its association with stomach adenocarcinoma proliferation and metastasis. Front Immunol. 2024;15:1466806.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04366-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04366-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04366-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:03:52Z","timestamp":1770397432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04366-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4366"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04366-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}